Table 3.

Evaluation of the experimental formulation during 12 months of intervention and 6 months of follow up in Lequesne Functional Index subscales

Lequesne subscales	SBCG1		SBCG2
	Score	Change from baseline	Score	Change from baseline
Pain
Baseline	5.4 (4.9, 5.9)a	-	5.5 (5.1, 5.9)	-
3 mo.	2.7 (2.1, 3.3)b	−3.0 (−7.5, −3.8)	2.4 (1.8, 3.1)	−2.9 (−3.6, −2.2)
8 mo.	2.0 (1.5, 2.6)	−3.4 (−9.0, −4.1)	1.9 (1.3, 2.6)	−3.5 (−4.3, −2.8)
12 mo.	1.4 (1.0, 1.9)	−3.8 (−9.9, −4.6)	1.7 (1.1, 2.4)	−3.9 (−4.6, −3.3)
18 mo.	1.3 (0.7, 1.9)	−3.8 (−8.8, −4.7)	1.7 (1.0, 2.4)	−4.0 (−4.7, −3.4)
Maximum walking distance
Baseline	4.2 (3.4, 5.1)	-	4.2 (3.6, 4.8)	-
3 mo.	1.8 (0.9, 2.6)	−2.9 (−6.4, −3.8)	2.2 (1.5, 2.9)	−1.9 (−2.7, −1.2)
8 mo.	1.2 (0.5, 1.9)	−3.2 (−6.8, −4.2)	1.4 (0.8, 1.9)	−2.9 (−3.7, −2.1)
12 mo.	1.1 (0.4, 1.8)	−3.2 (−6.7, −4.2)	1.2 (0.6, 1.8)	−3.3 (−4.1, −2.5)
18 mo.	0.7 (−0.1, 1.4)	−3.3 (−6.0, −4.4)	0.7 (0.2, 1.2)	−3.7 (−4.4, −2.9)
Daily activities
Baseline	8.0 (6.8, 9.2)	-	7.5 (6.7, 8.3)	-
3 mo.	4.0 (3.3, 4.8)	−4.4 (−5.7, −6.0)	3.9 (3.3, 4.6)	−3.7 (−4.6, −2.8)
8 mo.	3.5 (2.9, 4.2)	−4.7 (−6.3, −6.2)	3.5 (2.9, 4.1)	−4.2 (−5.2, −3.2)
12 mo.	2.8 (2.2, 3.4)	−4.9 (−7.8, −6.2)	3.3 (2.6, 4.0)	−4.7 (−5.8, −3.6)
18 mo.	2.8 (2.1, 3.6)	−4.5 (−6.3, −6.0)	2.9 (2.2, 3.7)	−5.0 (−6.4, −3.5)
Global score
Baseline	17.6 (15.5, 19.8)	-	17.2 (15.9, 18.5)	-
3 mo.	8.5 (6.7, 10.2)	−10.3 (−8.6, −12.7)	8.6 (7.0, 10.2)	−8.6 (−10.2, −6.9)
8 mo.	6.8 (5.2, 8.3)	−11.3 (−8.7, −13.9)	6.8 (5.3, 8.3)	−10.6 (−12.5, −8.8)
12 mo.	5.3 (3.8, 6.8)	−11.9 (−10.4, −14.2)	6.2 (4.6, 7.8)	−11.9 (−13.8, −10.0)
18 mo.	4.8 (3.1, 6.4)	−11.6 (−8.9, −14.4)	5.3 (3.7, 6.9)	−12.7 (−14.8, −10.5)

^aAll values are means (95% confidence interval).

^bAll post-treatment measurements were significantly different from baseline value.

There were no significant differences between treatments.